Posttherapy [ 18 F]FDOPA PET Findings in an Anaplastic Pleomorphic Xanthoastrocytoma With a BRAF V600E Mutation.
Jacopo Passoni, Andrea Rossi, Claudia Milanaccio et al.
✦ AI-curated · Sources linked
Case in brief
A 10-year-old boy with a left temporal anaplastic pleomorphic xanthoastrocytoma (APXA) carrying a BRAF V600E mutation presented with generalized tonic-clonic seizures occurring 3–4 times weekly. He was treated with combined BRAF and MEK inhibition. Posttherapy [18F]FDOPA PET provided metabolic information that preceded and complemented findings on conventional imaging, supporting its use in monitoring targeted therapy in this case.
What made this case unusual
The report highlights [18F]FDOPA PET as providing metabolic information before conventional imaging findings during targeted therapy monitoring.
Diagnostic / clinical pearl
In this case of BRAF V600E-mutant APXA, [18F]FDOPA PET offered metabolic information that preceded and complemented conventional imaging during treatment monitoring.